-
公开(公告)号:US07135487B2
公开(公告)日:2006-11-14
申请号:US10447619
申请日:2003-05-29
申请人: Macklin B Arnold , Stephen R Baker , Thomas J Bleisch , Buddy E Cantrell , Ana M Escribano , Ken Matsumoto , Tracey E McKennon , Paul L Ornstein , Richard L Simon , Edward C. R. Smith , Hamideh Zarrinmayeh , Dennis M Zimmerman
发明人: Macklin B Arnold , Stephen R Baker , Thomas J Bleisch , Buddy E Cantrell , Ana M Escribano , Ken Matsumoto , Tracey E McKennon , Paul L Ornstein , Richard L Simon , Edward C. R. Smith , Hamideh Zarrinmayeh , Dennis M Zimmerman
IPC分类号: A61K31/44 , C07D213/06 , C07D333/12 , C07C255/03 , C07C303/00
CPC分类号: A61K31/18 , A61K31/381 , A61K31/41 , A61K31/42 , A61K31/4245 , A61K31/4418 , A61K31/451 , A61K31/455 , C07C307/08 , C07C311/03 , C07C311/04 , C07C311/05 , C07C311/06 , C07C311/09 , C07C311/14 , C07C311/16 , C07C311/24 , C07C311/29 , C07C311/39 , C07C311/53 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/42 , C07D207/277 , C07D211/18 , C07D211/28 , C07D213/42 , C07D213/81 , C07D213/82 , C07D239/26 , C07D257/04 , C07D261/08 , C07D261/10 , C07D261/18 , C07D271/06 , C07D277/24 , C07D277/28 , C07D277/56 , C07D277/66 , C07D279/02 , C07D307/12 , C07D307/52 , C07D307/68 , C07D307/71 , C07D333/16 , C07D333/20 , C07D333/22 , C07D333/28 , C07D333/34 , C07D333/38 , C07D333/58 , C07D333/68 , C07D409/04
摘要: The present invention relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
摘要翻译: 本发明涉及新型磺酰胺衍生物,其制备方法和含有它们的药物组合物。
-
公开(公告)号:US06303816B1
公开(公告)日:2001-10-16
申请号:US09355605
申请日:1999-10-18
申请人: Macklin B Arnold , Stephen R Baker , David Bleakman , Thomas J Bleisch , Buddy E Cantrell , Ana M Escribano , Ken Matsumoto , Tracey E McKennon , Paul L Ornstein , Richard L Simon , Edward C. R. Smith , Joseph P Tizzano , Hamideh Zarrinmayeh , Dennis M Zimmerman
发明人: Macklin B Arnold , Stephen R Baker , David Bleakman , Thomas J Bleisch , Buddy E Cantrell , Ana M Escribano , Ken Matsumoto , Tracey E McKennon , Paul L Ornstein , Richard L Simon , Edward C. R. Smith , Joseph P Tizzano , Hamideh Zarrinmayeh , Dennis M Zimmerman
IPC分类号: C07C3103
CPC分类号: A61K31/18 , A61K31/381 , A61K31/41 , A61K31/42 , A61K31/4245 , A61K31/4418 , A61K31/451 , A61K31/455 , C07C307/08 , C07C311/03 , C07C311/04 , C07C311/05 , C07C311/06 , C07C311/09 , C07C311/14 , C07C311/16 , C07C311/24 , C07C311/29 , C07C311/39 , C07C311/53 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/42 , C07D207/277 , C07D211/18 , C07D211/28 , C07D213/42 , C07D213/81 , C07D213/82 , C07D239/26 , C07D257/04 , C07D261/08 , C07D261/10 , C07D261/18 , C07D271/06 , C07D277/24 , C07D277/28 , C07D277/56 , C07D277/66 , C07D279/02 , C07D307/12 , C07D307/52 , C07D307/68 , C07D307/71 , C07D333/16 , C07D333/20 , C07D333/22 , C07D333/28 , C07D333/34 , C07D333/38 , C07D333/58 , C07D333/68 , C07D409/04
摘要: Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formula R1—L—NHSO2R2 I in which R1 represents an unsubstituted or substituted aromatic or heteroaromatic group; R2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C)chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R3R4N in which R3 and R4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; and L represents a (2-4C)alkylene chain which is unsubstituted or substituted by one or two substituents selected independently from (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl, aryl(2-6C)alkenyl and aryl, or by two substituents which, together with the carbon atom or carbon atoms to which they are attached form a (3-8C)carbocyclic ring; and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula I, processes for preparing them and pharmaceutical compositions containing them.
摘要翻译: 哺乳动物的谷氨酸受体功能可以使用有效量的化合物,R1表示未取代或取代的芳族或杂芳族基团,R2表示(1-6C)烷基,(3-6C)环烷基,(1-6C) 氟代烷基,(1-6C)氯烷基,(2-6C)烯基,(1-4C)烷氧基(1-4C)烷基,未被取代或被卤素取代的苯基,(1-4C)烷基或(1-4C) 烷氧基或式R3R4N的基团,其中R3和R4各自独立地表示(1-4C)烷基,或者与它们所连接的氮原子一起形成氮杂环丁烷基,吡咯烷基,哌啶基,吗啉代,哌嗪基,六氢氮杂或八氢吖辛因 组; 和(1-6C)烷基,芳基(1-6C)烷基,(2-6C)链烯基,芳基(2-6C)烷基,(1-6C)烷基, )烯基和芳基,或两个与它们所连接的碳原子或碳原子一起形成(3-8C)碳环的取代基;及其药学上可接受的盐。还公开了式I的化合物, 制备它们和含有它们的药物组合物。
-